$3250 | Single User
$6500 | Site License
$9750 | Enterprise License

Metastatic Renal Cell Carcinoma (mRCC) - Epidemiology Forecast to 2027
[Report Updated: 14-02-2018]

Published by Delve Insight: 14 Feb 2018 | 201493 | In Stock
Related Topics: Renal Cell Carcinoma

Introduction

DelveInsight's "Metastatic Renal Cell Carcinoma (mRCC) - Epidemiology Forecast, 2027” report provides a comprehensive analysis of the Metastatic Renal Cell Carcinoma (mRCC) epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2027.

Markets Covered

• United States

• EU5 (Germany, France, Italy, Spain, and the United Kingdom)

• Japan

Study Period: 2016-2027

Metastatic Renal Cell Carcinoma (mRCC) Epidemiology

The epidemiology section covers the historical, current as well as forecasted epidemiology for Metastatic Renal Cell Carcinoma (mRCC) in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Metastatic Renal Cell Carcinoma (mRCC) outlook. It also includes the explanation of changing trends of epidemiology outlining the Metastatic Renal Cell Carcinoma (mRCC) scenario.

Metastatic Renal Cell Carcinoma (mRCC) Epidemiology Segmentation

The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Metastatic Renal Cell Carcinoma (mRCC) thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope

• The report covers detailed overview of Metastatic Renal Cell Carcinoma (mRCC) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns

• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan

• The Metastatic Renal Cell Carcinoma (mRCC) Report assesses the disease risk and burden and highlights the unmet needs

• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths

• 10 Year Forecast

• 7MM Coverage

• Total Cases in Metastatic Renal Cell Carcinoma (mRCC)

Key assessments

• Patient Segmentation in Metastatic Renal Cell Carcinoma (mRCC)

• Metastatic Renal Cell Carcinoma (mRCC) Risk & Burden

• Factors driving growth in a specific Metastatic Renal Cell Carcinoma (mRCC) patient population

Table of Contents
for Metastatic Renal Cell Carcinoma (mRCC) - Epidemiology Forecast to 2027 [Report Updated: 14-02-2018]

  • 1. Report Introduction

    2. Metastatic Renal Cell Carcinoma (mRCC) Epidemiology Overview at a Glance

    2.1. Patient Share Distribution of Metastatic Renal Cell Carcinoma (mRCC) in 2017

    2.2. Patient Share Distribution of Metastatic Renal Cell Carcinoma (mRCC) in 2027

    3. Disease Background and Overview: Metastatic Renal Cell Carcinoma (mRCC)

    3.1. Introduction

    3.2. Symptoms

    3.3. Etiology

    3.4. Risk Factors

    3.5. Pathophysiology

    3.6. Diagnosis

    3.7. Treatment

    4. Epidemiology and Patient Population

    4.1. Key Findings

    4.2. Total Prevalent/ Incident Patient Population of Metastatic Renal Cell Carcinoma (mRCC) in 7MM

    4.3. Total Prevalent/ Incident Patient Population of Metastatic Renal Cell Carcinoma (mRCC) in 7MM – By Countries

    5. Epidemiology of Metastatic Renal Cell Carcinoma (mRCC) by Countries

    5.1. United States

    5.1.1. Assumptions and Rationale

    5.1.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC)

    5.1.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) *

    5.1.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) *

    5.1.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC)

    5.2. EU5

    5.3. Assumptions and Rationale

    5.4. Germany

    5.4.1. Assumptions and Rationale

    5.4.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC)

    5.4.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) *

    5.4.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) *

    5.4.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC)

    5.5. France

    5.5.1. Assumptions and Rationale

    5.5.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC)

    5.5.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) *

    5.5.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) *

    5.5.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC)

    5.6. Italy

    5.6.1. Assumptions and Rationale

    5.6.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC)

    5.6.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) *

    5.6.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) *

    5.6.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC)

    5.7. Spain

    5.7.1. Assumptions and Rationale

    5.7.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC)

    5.7.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) *

    5.7.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) *

    5.7.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC)

    5.8. United Kingdom

    5.8.1. Assumptions and Rationale

    5.8.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC)

    5.8.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) *

    5.8.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) *

    5.8.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC)

    5.9. Japan

    5.9.1. Assumptions and Rationale

    5.9.2. Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC)

    5.9.3. Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) *

    5.9.4. Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) *

    5.9.5. Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC)

    6. Unmet Needs of the Metastatic Renal Cell Carcinoma (mRCC)

    7. Appendix

    8. Report Methodology

    8.1. Sources

    9. DelveInsight Capabilities

    10. Disclaimer

    11. About DelveInsight

    *Indication Specific

List Of Tables
in Metastatic Renal Cell Carcinoma (mRCC) - Epidemiology Forecast to 2027 [Report Updated: 14-02-2018]

Table 1: Total Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in 7MM

Table 2: Total Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2027)

Table 4: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2027)*

Table 5: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2027)*

Table 6: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2027)

Table 7: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2027)

Table 8: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2027) *

Table 9: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2027) *

Table 10: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2027)

Table 11: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2027)

Table 12: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2027) *

Table 13: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2027) *

Table 14: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2027)

Table 15: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2027)

Table 16: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2027) *

Table 17: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2027) *

Table 18: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2027)

Table 19: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2027)

Table 20: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2027) *

Table 21: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2027) *

Table 22: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2027)

Table 23: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2027)

Table 24: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2027) *

Table 25: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2027) *

Table 26: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2027)

Table 27: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2027)

Table 28: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2027) *

Table 29: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2027) *

Table 30: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2027)

List Of Figures, Charts and Diagrams
in Metastatic Renal Cell Carcinoma (mRCC) - Epidemiology Forecast to 2027 [Report Updated: 14-02-2018]

Table 1: Total Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in 7MM

Table 2: Total Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in 7MM by Countries

Table 3: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2027)

Table 4: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2027)*

Table 5: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2027)*

Table 6: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in United States (2016-2027)

Table 7: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2027)

Table 8: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2027) *

Table 9: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2027) *

Table 10: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Germany (2016-2027)

Table 11: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2027)

Table 12: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2027) *

Table 13: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2027) *

Table 14: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in France (2016-2027)

Table 15: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2027)

Table 16: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2027) *

Table 17: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2027) *

Table 18: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Italy (2016-2027)

Table 19: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2027)

Table 20: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2027) *

Table 21: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2027) *

Table 22: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Spain (2016-2027)

Table 23: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2027)

Table 24: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2027) *

Table 25: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2027) *

Table 26: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in UK (2016-2027)

Table 27: Prevalent/Incident Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2027)

Table 28: Sub-Type Specific cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2027) *

Table 29: Sex- Specific Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2027) *

Table 30: Diagnosed Cases of the Metastatic Renal Cell Carcinoma (mRCC) in Japan (2016-2027)

Additional Details

Publisher

Delve Insight

Publisher Information

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.



We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Reference

201493 | DIEI0143

Number of Pages

50

Report Format

PDF

Delve Insight Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016
Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial r...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016
Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016
Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial ...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016
Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical ...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H2, 2016
Metastatic Hepatocellular Carcinoma (HCC) Global Clinical Trials Review, H2, 2016SummaryGlobalData's...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016
Metastatic Breast Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial r...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016
Metastatic Prostate Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016
Metastatic Ovarian Cancer Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical trial ...
29 Jul 2016 by Global Data USD $2,500 More Info
Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016
Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical ...
29 Jul 2016 by Global Data USD $2,500 More Info
Physician Views: Avastin to lose share as front-line therapy for first-line metastatic colorectal cancer?
Scope Two recent developments appear poised to shift the typical US-based treatment regimen for firs...
13 Jul 2014 by FirstWord Pharma USD $695 More Info

This report is published by Delve Insight

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Download Free Report Summary PDF

Metastatic Renal Cell Carcinoma (mRCC) - Epidemiology Forecast to 2027 [Report Updated: 14-02-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • 360i Research
  • 99Strategy
  • Allied Market Research
  • Asia Market Information & Development Co.
  • Azoth Analytics
  • BioInformant
  • Black Swan Analysis
  • Canadean
  • CBR Pharma Insights
  • CRI
  • Current Analysis
  • Current Partnering
  • Daedal Research
  • Data bridge
  • Delve Insight
  • DPI Research
  • FirstWord Pharma
  • Future Market Insights
  • GBI Research
  • Global Data
  • Global Markets Direct
  • Global Research and Data Services GRDS
  • GMR Data
  • HeyReport
  • HongChun
  • HTStec
  • ICD Research
  • iGATE Research
  • IMARC
  • Industry ARC
  • Inkwood Research
  • IQ4I
  • Jain PharmaBiotech
  • Kelly Scientific
  • La Merie
  • Lifescience Intellipedia
  • LP Information
  • Market Data Forecast
  • Market Research Future
  • Marketline
  • MarketsandMarkets
  • McDerson
  • MedMarket Diligence
  • Meticulous Research
  • MicroMarketMonitor
  • MIReports
  • Mordor Intelligence LLC
  • MP Advisors
  • Occams Business Research
  • Prof Research
  • Progressive Markets
  • ProGrow Pharma Partners
  • Renub
  • Research Impact
  • RNCOS
  • Rockville Research
  • S&P Consulting
  • StratisticsMRC
  • The Business Research Company
  • Triton Market Research
  • Venture Planning Group (VPG)